Ligand Pharmaceuticals (LGND) Liabilities from Discontinued Operations (2021 - 2025)
Ligand Pharmaceuticals' (LGND) quarterly Liabilities from Discontinued Operations came in at 35692000.0 in Q2 2025, up 39.92% quarter-over-quarter from 25509000.0 in Q1 2025.
Ligand Pharmaceuticals (LGND) Liabilities from Discontinued Operations (2021 - 2025) Analysis & Trends
Ligand Pharmaceuticals has disclosed Liabilities from Discontinued Operations across 2 years of filings, most recently posting 35692000.0 for Q2 2025.
- Liabilities from Discontinued Operations for Q2 2025 came in at 35692000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was 35692000.0 (changed N/A YoY), and the FY2021 annual result was 55528000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations came in at 35692000.0 for Q2 2025 at Ligand Pharmaceuticals, up from 25509000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 55528000.0 in Q4 2021 to a low of 25509000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.47 Bn | 4.69 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 35.69 Mn |
| Jun 30, 2025 | 35.69 Mn |
| Mar 31, 2025 | 25.51 Mn |
| Mar 31, 2025 | 25.51 Mn |
| Dec 31, 2021 | 55.53 Mn |
| Dec 31, 2021 | 55.53 Mn |